Borderline T cell-mediated rejection is a diagnostic category of the Banff schema that uses a lower diagnostic threshold. Subclinical borderline T cell-mediated rejection detected by surveillance sampling is not entirely benign. Studies demonstrate increased rates of late rejection, progressive nephron loss, functional impairment, donor-specific antibody formation, and allograft failure. It can be conceptualized as a failure to control the cellular alloimmune response. Mixed results are reported for its treatment, and randomized controlled trials are needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.kint.2020.04.052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The outcome of thrombotic microangiopathy in kidney transplant recipients.
BMC Nephrol
November 2024
Department of Medicine, Johns Hopkins Hospital, The Johns Hopkins University School of Medicine, 600 Wolfe St. Carnegie 344B, Baltimore, MD, 21287, USA.
Background: The outcome of kidney transplant recipients with a history of complement-mediated thrombotic microangiopathy (cTMA) and those who develop post-transplant de novo TMA (dnTMA) is largely unknown.
Methods: We retrospectively studied all kidney transplant recipients with end-stage kidney disease secondary to cTMA and those who developed dnTMA, between Jan 2000 and Dec 2020 in our center.
Results: We identified 134 patients, 22 with cTMA and 112 had dnTMA.
Early Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients Followed-Up for Two Years: Experience of One Center.
Life (Basel)
November 2024
Immunology Service, University Clinical Hospital Virgen de la Arrixaca, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain.
(1) Background: donor-derived circulating free DNA (dd-cfDNA), an innovative biomarker with great potential for the early identification and prevention of graft damage. (2) Methods: Samples were collected prospectively and the study was performed retrospectively to analyze dd-cfDNA plasma levels in 30 kidney transplant patients during their post-transplant follow-up (15 days, 3, 6, and 9 months), to determine if the result could be of interest in the identification of possible adverse events, especially rejection. The aim was to verify whether the data on sensitivity, specificity, NPV, and PPV compare with reference values and creatinine values.
View Article and Find Full Text PDFClinical and Histopathological Findings in HIV-positive to HIV-positive Kidney Transplant Recipients.
Transplantation
November 2024
Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Background: The spectrum of histological findings in transplanted kidneys from HIV-positive donors to HIV-positive recipients is relatively unexplored. This study describes the type and timing of histological diagnoses observed in this unique cohort.
Methods: Adequate biopsies were analyzed at implantation and posttransplant between September 2008 and May 2022.
Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes.
Front Immunol
November 2024
Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Republic of Korea.
Article Synopsis
- ABO-incompatible kidney transplantation (KT) is increasingly used to address organ shortages, but high levels of anti-ABO antibodies can hinder successful transplantation despite existing desensitization methods.
- Eculizumab was used as an additional treatment to help patients with very high anti-ABO antibodies who did not respond to standard therapies, showing improvements in kidney function and antibody levels after transplant.
- The study indicates that short-term eculizumab treatment may effectively support ABOi KT patients by maintaining stable kidney function and reducing antibody levels, even in cases previously deemed challenging.
Archetypal Analysis of Kidney Allograft Biopsies Using Next-generation Sequencing Technology.
Transplantation
October 2024
Université Paris Cité, INSERM U970, Paris Institute for Transplantation and Organ Regeneration, Paris, France.
Background: In kidney transplantation, molecular diagnostics may be a valuable approach to improve the precision of the diagnosis. Using next-generation sequencing (NGS), we aimed to identify clinically relevant archetypes.
Methods: We conducted an Illumina bulk RNA sequencing on 770 kidney biopsies (540 kidney recipients) collected between 2006 and 2021 from 11 European centers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!